Metraipolis › archive › dc_ed87c83fbb11
Clinical outcomes of sotrovimab in seronegative patients with severe COVID-19: A multicenter retrospective study — Europe PMC PMID:41496008
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41496008
- DOI
- 10.1097/md.0000000000046382
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T04:38:44.811Z
- SHA-256 of the archived text
418aa6d3d7859eb99f3e07619a6ee1684434303c78d525f3cef65c6bcd5ee29e- Stable URL of this page
https://metraipolis.com/documento/dc_ed87c83fbb11
How to cite
Clinical outcomes of sotrovimab in seronegative patients with severe COVID-19: A multicenter retrospective study — Europe PMC PMID:41496008 — Europe PMC (en), https://europepmc.org/article/MED/41496008 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ed87c83fbb11 (Metraipolis archive dc_ed87c83fbb11, sha256 418aa6d3d7859eb99f3e07619a6ee1684434303c78d525f3cef65c6bcd5ee29e)
BibTeX
@misc{dced87c83fbb11,
title = {Clinical outcomes of sotrovimab in seronegative patients with severe COVID-19: A multicenter retrospective study — Europe PMC PMID:41496008},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41496008},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ed87c83fbb11; sha256 418aa6d3d7859eb99f3e07619a6ee1684434303c78d525f3cef65c6bcd5ee29e},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41496008. Agents can read the archived copy with the MCP tool read_document.